Compugen (CGEN) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Compugen (NASDAQ:CGEN) from a sell rating to a hold rating in a report released on Tuesday.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, ValuEngine downgraded Compugen from a sell rating to a strong sell rating in a report on Sunday, December 31st.
A hedge fund recently bought a new stake in Compugen stock. Susquehanna International Group LLP acquired a new position in Compugen Ltd. (NASDAQ:CGEN) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 42,597 shares of the biotechnology company’s stock, valued at approximately $162,000. Susquehanna International Group LLP owned approximately 0.08% of Compugen at the end of the most recent quarter. 17.43% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/compugen-cgen-upgraded-at-zacks-investment-research/1801955.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.